Drugs News and Research RSS Feed - Drugs News and Research

Scientists reveal how disruption of DISC1 gene involved in mental illness affects the brain

Scientists reveal how disruption of DISC1 gene involved in mental illness affects the brain

Scientists have for the first time shown how the disruption of a key gene involved in mental illness impacts on the brain. [More]
Aptensio XR once-daily treatment for ADHD to be available in Summer 2015

Aptensio XR once-daily treatment for ADHD to be available in Summer 2015

Today, Rhodes Pharmaceuticals L.P. announced that Aptensio XR, a once-daily central nervous system stimulant indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will be available to patients beginning Summer 2015. [More]
Clinical genomic sequencing could impact treatment decisions in advanced prostate cancer patients

Clinical genomic sequencing could impact treatment decisions in advanced prostate cancer patients

An international collaboration of researchers are advancing precision medicine to men with advanced prostate cancer. [More]
TGen and Baylor partnership set to increase treatment options for cancer patients

TGen and Baylor partnership set to increase treatment options for cancer patients

The Translational Genomics Research Institute (TGen) and Baylor Research Institute (BRI) at Dallas today announce an agreement that will focus on accelerating early detection and treatments for patients with a broad range of cancers. [More]
Scientists find new way to convert blood cells into sensory neurons

Scientists find new way to convert blood cells into sensory neurons

Scientists at McMaster University have discovered how to make adult sensory neurons from human patients simply by having them roll up their sleeve and providing a blood sample. [More]
LSDF awards $2.9 million in funding to help commercialize major medical breakthroughs

LSDF awards $2.9 million in funding to help commercialize major medical breakthroughs

Celiac disease-safe wheat, premature infant pain detection, and new medicines to fight flu and cancer are among the ideas to receive $2.9 million in funding from Washington's Life Sciences Discovery Fund (LSDF). [More]
GHIT Fund expands investments in leishmaniasis, diagnostic tests

GHIT Fund expands investments in leishmaniasis, diagnostic tests

The Global Health Innovative Technology Fund, which in the last two years has funded almost $32 million for innovative tools to tackle global infectious diseases, today announced additional investments of nearly $11 million that bring its portfolio to approximately $43 million. [More]
Chemical compound shows promise in treating rheumatoid arthritis

Chemical compound shows promise in treating rheumatoid arthritis

Montana State University researchers and their collaborators have published their findings about a chemical compound that shows potential for treating rheumatoid arthritis. [More]
UH pharmacy students receive awards for excellence in clinical skills, disease management

UH pharmacy students receive awards for excellence in clinical skills, disease management

University of Houston pharmacy students wrapped up the spring semester with awards for excellence in professional service, clinical skills and disease management, earning kudos at the state level from the Texas Society of Health-System Pharmacists. [More]
Risk prediction model can help target hepatitis C treatment to patients with most urgent need

Risk prediction model can help target hepatitis C treatment to patients with most urgent need

A team of researchers at the University of Michigan Health System has developed a risk prediction model that helps identify which hepatitis C patients have the most urgent need for new anti-viral drugs. [More]
RCC benefit independent of sorafenib, sunitinib sequence order

RCC benefit independent of sorafenib, sunitinib sequence order

Sequential treatment with sorafenib followed by sunitinib is not superior to sunitinib followed by sorafenib in patients with advanced or metastatic renal cell carcinoma, suggests research published in European Urology. [More]
Certain proteins may slow cognitive decline in people with Alzheimer's disease

Certain proteins may slow cognitive decline in people with Alzheimer's disease

Certain proteins may slow the devastating memory loss caused by Alzheimer's disease, according to a groundbreaking Iowa State University study. [More]
Nanoparticle-based therapy effective in treating mice with multiple myeloma

Nanoparticle-based therapy effective in treating mice with multiple myeloma

Researchers have designed a nanoparticle-based therapy that is effective in treating mice with multiple myeloma, a cancer of immune cells in the bone marrow. [More]

Canada lagging behind similar OECD countries with regard to public drug plan reimbursement

Canadians face wait times of over 460 days in order to get access to new, potentially lifesaving medicines in public drug plans, according to a new IMS Brogan report commissioned by Rx&D. Overall, the report ranks Canada 16 out of 18 similar OECD countries. [More]
FDA accepts Tris Pharma's Dyanavel XR NDA for review

FDA accepts Tris Pharma's Dyanavel XR NDA for review

Tris Pharma, Inc. announced that U.S. Food and Drug Administration has accepted for review its New Drug Application ("NDA") for Dyanavel XR (amphetamine) CII, an Extended-Release Oral Suspension. [More]

Banook Group consolidates three subsidiaries under one unique name and brand

Banook Group, an international provider of cardiac safety, central imaging and endpoint adjudication services, today announces that its three subsidiaries will now be combined into one unique name and brand. [More]
Second-generation antibiotic shows promise against common bacterial infections

Second-generation antibiotic shows promise against common bacterial infections

Researchers led by St. Jude Children's Research Hospital scientists have developed a second-generation antibiotic that shows early effectiveness against common bacterial infections that pose a serious health threat to children and adults. [More]
SARIL-RA-TARGET trial: Sarilumab meets co-primary efficacy endpoints in RA patients

SARIL-RA-TARGET trial: Sarilumab meets co-primary efficacy endpoints in RA patients

Regeneron Pharmaceuticals, Inc. and Sanofi announced today that a Phase 3 study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis (RA) at 24 weeks and physical function at 12 weeks, compared to placebo. [More]
Researchers find that blocking MCAM molecule could slow progression of multiple sclerosis

Researchers find that blocking MCAM molecule could slow progression of multiple sclerosis

A drug that could halt the progression of multiple sclerosis may soon be developed thanks to a discovery by a team at the CHUM Research Centre and the University of Montreal. The researchers have identified a molecule called MCAM, and they have shown that blocking this molecule could delay the onset of the disease and significantly slow its progression. [More]
Non-coding micro RNA molecule may control chemotherapy resistance among ovarian cancer patients

Non-coding micro RNA molecule may control chemotherapy resistance among ovarian cancer patients

A molecule that helps control gene expression may play a role in controlling chemotherapy resistance among patients with the most common form of ovarian cancer. [More]
Advertisement
Advertisement